IRON REGULATION BY MOLIDUSTAT, BAY 85-3934, A DAILY ORAL HYPOXIA-INDUCIBLE FACTOR PROLYL HYDROXYLASE INHIBITOR IN PATIENTS WITH CHRONIC KIDNEY DISEASE

被引：0
|
作者：
Akizawa, Tadao [6 ]
Macdougall, Iain C. [5 ]
Berns, Jeffrey S. [4 ]
Bernhardt, Thomas [1 ]
Taguchi, Megumi [2 ]
Ogura, Eriko [3 ]
Lekushi, Kazuma [2 ]
机构：
[1] Bayer AG, Pharmaceut, Berlin, Germany
[2] Bayer Yakuhin Ltd, Med Affairs, Osaka, Japan
[3] Bayer Yakuhin Ltd, Prod Dev, Osaka, Japan
[4] Hosp Univ Penn, Nephrol, 3400 Spruce St, Philadelphia, PA 19104 USA
[5] Kings Coll Hosp London, Nephrol, London, England
[6] Showa Univ, Sch Med, Div Nephrol, Tokyo, Japan
来源：
NEPHROLOGY DIALYSIS TRANSPLANTATION | 2018年 / 33卷
关键词：
D O I：
暂无
中图分类号：
R3 [基础医学]; R4 [临床医学];
学科分类号：
1001 ; 1002 ; 100602 ;
摘要：
SP334
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Iron Regulation by Molidustat, a Daily Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor, in Patients with Chronic Kidney Disease
    Akizawa, Tadao
    Macdougall, Iain C.
    Berns, Jeffrey S.
    Yamamoto, Hiroyasu
    Taguchi, Megumi
    Iekushi, Kazuma
    Bernhardt, Thomas
    [J]. NEPHRON, 2019, 143 (04) : 243 - 254
  • [2] Use of molidustat, a hypoxia-inducible factor prolyl hydroxylase inhibitor, in chronic kidney disease-associated anemia in cats
    Charles, Samuel
    Suessenberger, Ricarda
    Settje, Terry
    Langston, Catherine
    Lainesse, Chantal
    [J]. JOURNAL OF VETERINARY INTERNAL MEDICINE, 2024, 38 (01) : 197 - 204
  • [3] Hypoxia-inducible factor prolyl hydroxylase inhibitor in the treatment of anemia in chronic kidney disease
    Kurata, Yu
    Tanaka, Tetsuhiro
    Nangaku, Masaomi
    [J]. CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION, 2020, 29 (04): : 414 - 422
  • [4] Daprodustat: A Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor for Anemia of Chronic Kidney Disease
    Johnson, Haley N.
    Prasad-Reddy, Lalita
    [J]. ANNALS OF PHARMACOTHERAPY, 2024,
  • [5] Discovery of molidustat (BAY 85-3934): A small-molecule oral HIF-prolyl hydroxylase (HIF-PH) inhibitor for the treatment of renal anemia
    Beck, Hartmut
    [J]. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2017, 254
  • [6] Hypoxia-inducible factor?prolyl hydroxylase inhibitors in the treatment of anemia of chronic kidney disease
    Haase, Volker H.
    [J]. KIDNEY INTERNATIONAL SUPPLEMENTS, 2021, 11 (01) : 8 - 25
  • [7] Daprodustat Hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitor Treatment of anemia associated with chronic kidney disease
    Gras, J.
    [J]. DRUGS OF THE FUTURE, 2017, 42 (06) : 327 - 333
  • [8] Hypoxia-inducible factor-prolyl hydroxylase inhibitor ameliorates myopathy in a mouse model of chronic kidney disease
    Qian, Fang-Yuan
    Li, Zuo-Lin
    Guo, Yu-Dong
    Gao, Han-Chao
    Gu, Li-Hua
    Le, Kai
    Xie, Chun-Ming
    Wang, Bin
    Zhang, Zhi-Jun
    [J]. AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY, 2019, 317 (05) : F1265 - F1273
  • [9] VADADUSTAT Hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitor Treatment of anemia secondary to chronic kidney disease
    Cole, P.
    [J]. DRUGS OF THE FUTURE, 2016, 41 (10) : 601 - 606
  • [10] Evolution of hypoxia and hypoxia-inducible factor asparaginyl hydroxylase regulation in chronic kidney disease
    Faivre, Anna
    Dissard, Romain
    Kuo, Willy
    Verissimo, Thomas
    Legouis, David
    Arnoux, Gregoire
    Heckenmeyer, Carolyn
    Fernandez, Marylise
    Tihy, Matthieu
    Rajaram, Renuga D.
    Delitsikou, Vasiliki
    Le, Ngoc An
    Spingler, Bernhard
    Mueller, Bert
    Shulz, Georg
    Lindenmeyer, Maja
    Cohen, Clemens
    Rutkowski, Joseph M.
    Moll, Solange
    Scholz, Carsten C.
    Kurtcuoglu, Vartan
    de Seigneux, Sophie
    [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 2023, 38 (10) : 2276 - 2288
12345